ZUMA-2 is a phase 2 trial which evaluated the efficacy of brexu-cel in patients with relapsed or refractory MCL who had received up to five previous therapies, including a monoclonal antibody, anthracycline- or bendamustine-based chemotherapy, and a BTK inhibitor. This evidence concerns the gene BTK and mantle cell lymphoma.